LONDON, November 8 /PRNewswire/ -- Germany-based, biotechnology company Eppendorf AG has been conferred the 2005 Frost & Sullivan Technology Innovation Award in recognition of its unique contribution to molecular technologies. The company has effectively leveraged its flagship DualChip(r) Microarray technology in prospective drug discovery and clinical research applications.
Through its optimal hybridization efficiency, the DualChip(r) Microarray technology aims to harness the enormous potential for studying homologous gene sequences. In offering more accurate results than conventional DNA microarrays, the DualChip(r) Microarray is proving to be a future key tool in assisting the diagnostics industry. Prominent features in this array technology include two identical arrays housed in an easy-to-fill hybridization frame and a microarray control probe that enables expert signal linearity by closely monitoring the hybridization efficiency.
With customer-friendliness emerging as a critical product differentiator, Eppendorf AG’s introduction of a simplified, user-friendly array technology is supporting scientists in their bench work in drug discovery and while developing diagnostic solutions. As multi-parameter testing of different gene expressions gives microarrays an advantage over conventional single parameter tests, Eppendorf AG has made provisions for one-colour gene expression methods.
“On the DualChip(r) array, the diseased tissue sample may be treated on one chip and compared with the healthy tissue control on the other chip. This technology will help identify relevant biomarkers of interest, and thus assist in tracking the disease progression in a cost-effective manner,” notes Frost & Sullivan Research Analyst Charanya Ramachandran.
“Data Read outs from Eppendorf AG’s system can be evaluated with customer-friendly software that may help researchers not only comprehend the experiments but, more importantly, also corroborate whether the experiment answers their relevant biomedical issues,” she adds.
Directing its efforts toward the designing of innovative, genomics-oriented tools, Eppendorf AG aims at improving the quality of future therapeutics.
The DualChip(r) human RNAi side effect array represents another notable achievement of the company. Among the principal benefits of the RNAi arrays are its low-cost solutions for different stages of the drug discovery process and the ability to reduce drug attrition rates, especially at the later stages. This array utilises a prefabricated low-density system that delivers statistically evaluated results, thereby facilitating research. A series of thorough evaluations can be done before drug targets are scored through different phases of compound screening.
“Given that Eppendorf AG continues to exhibit outstanding dedication to bioresearch, both in-house and through possible alliances and acquisitions, Frost & Sullivan expects Eppendorf AG to improve its standing in the European biochips for clinical research applications market in the near term,” concludes Ms. Ramachandran.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
Media Contact: Janina Hillgrub Corporate Communications Frost & Sullivan Phone: +49-69-77033-11 Fax: +49-69-234566 E-Mail: janina.hillgrub@frost.com
Frost & Sullivan
CONTACT: Media Contact: Janina Hillgrub, Corporate Communications, Frost &Sullivan, Phone: +49-69-77033-11, Fax: +49-69-234566, E-Mail:janina.hillgrub@frost.com
